Top Markets
#1 PulseChain PulseChain +45.01%
#2 SkyAI SkyAI +12.67%
#3 Meteora Meteora +11.24%
#4 Glidr Glidr +9.27%
#5 OPENLOOT OPENLOOT +8.94%
#6 Unit Pump Unit Pump +8.52%
#7 Pump.fun Pump.fun +8.52%
#8 Lorenzo Wrapped Bitcoin Lorenzo Wrapped Bitcoin +7.55%
#9 eCash eCash +7.18%
#10 Cash Cat Cash Cat +7.15%
Coin of the day
PulseChain PulseChain
설정
언어
한국어
통화
USD
테마
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
주식 순위 #28041
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
주가
$0.55
마지막 동기화: 2025-02-11
시가총액
$28.90M
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Marinus Pharmaceuticals, Inc. (MRNS)

카테고리

Healthcare
Marinus Pharmaceuticals, Inc. (MRNS)의 영업이익률
August 2026 기준 영업이익률 TTM: -424.30%
Marinus Pharmaceuticals, Inc.의 최신 재무 보고서와 주가에 따르면 현재 영업이익률 (TTM)은 -424.30%입니다. 2022년 말 기준 영업이익률은 -442.69%였습니다.
Marinus Pharmaceuticals, Inc.의 영업이익률 기록 (2012 ~ 2026)
매년 말 영업이익률
연도 영업이익률 변화
2026 (TTM) -424.30% 0.00%
2023 -424.30% -4.15%
2022 -442.69% -29.92%
2021 -631.68% -84.03%
2020 -3,954.42% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
2013 0.00% -100.00%
2012 -1,430.66% 0.00%
유사 기업 또는 경쟁사의 영업이익률
회사 영업이익률 영업이익률 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -100.09%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -99.65%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -100.07%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -100.06%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
회사의 영업이익률이란?
영업이익률은 회사의 수익성을 평가하는 핵심 지표입니다. 높은 영업이익률은 일반적으로 긍정적으로 간주되며, 이는 회사가 제품이나 서비스를 생산 비용보다 훨씬 높은 가격에 판매할 수 있음을 보여줍니다. 영업이익률은 회사의 수익을 매출로 나누어 계산합니다.